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Abstract
Aim To provide evidence for the effect of bevacizumab on
visual acuity (VA) and central retinal thickness (CRT) in
exudative age-related macular degeneration
Methods A systematic review of all articles of bevacizumab
for exudative AMD was conducted. Articles published up
to March 2008 were identified in Medline, Embase, the
Cochrane Controlled Trials Register and references from
included articles. Search terms were “Bevacizumab or
Avastin” and “Macula* or ARMD or AMD or intra(-)
vitreal or intra(-)vitreous”. Three observers participated in
the data retrieval and assignment of the quality scores.
Results A total of 561 articles were retrieved. Three
randomised controlled trials (RCT) and 23 before-and-after
studies of patients (n=1,435) who had received bevacizu-
mab were published. Inclusion criteria varied. Lack of
masking was the main methodological shortcoming. These
RCTs showed that bevacizumab is more effective than
PDT. Bevacizumab was given intravenously or as intra-
vitreal injection. The latter was given once, or repeatedly
every 4 weeks, and with or without additional injection
when a recurrence occurred, mostly based on visual acuity
and/or findings from optical coherence tomography. After
intravenous administration, the weighted mean change in
VA was +12.8 ETDRS letters (range +11 to +14) and the
weighted mean change for CRT was −129 μm (range −100
to −202). For the 23 studies with intravitreal injections,
the change in VA was +8.6 letters (range +2 to +26) and
the change in CRT was −90 μm (range −46 to −190). The
incidence of adverse events was low. The change in VA
was 2.7 letters higher for studies with a higher quality vs
lower quality.
Conclusion Visual acuity improves and central retinal
thickness decreases in patients with exudative AMD after
bevacizumab. There is no reasonable doubt that this is
caused by bevacizumab. It is likely that a randomised
controlled trial will show that bevacizumab is equivalent in
effect to ranibizumab, which showed a change in ETDRS
of +5.9 letters for occult or minimally classic CNVand +9.8
letters for classic CNV after three monthly injections in two
large RCTs.
Keywords Systematic review . Bevacizumab . Exudative
macular degeneration . Visual acuity . Retinal thickness
Introduction
Age-related macular degeneration (AMD) is the leading
cause of severe blindness in the elderly in Western
countries [11, 13]. Exudative macular degeneration is the
most severe form with the highest risk of blindness [13].
Vision loss is the result of macular haemorrhage and fluid
caused by leakage from subfoveal choroidal neovascular-
isation (CNV), which is the hallmark of exudative AMD.
Vascular endothelial growth factors (VEGF) have a key role
in the formation and leakage of CNV [28]. Recently, the
anti-VEGFs pegabtanib and ranibizumab became available
for the treatment of exudative AMD [12, 36, 38, 43, 45]. In
contrast to pegabtanib, intravitreal injections with ranibizu-
mab led to a significant vision improvement. In fact,
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ranibizumab was the first drug to improve vision in
exudative AMD, compared to interventions used earlier
which only delayed progression [12, 38]. Major disadvan-
tages of this intervention are the costs and the need to give
intravitreal injections repeatedly. Bevacizumab, which is
approved for the treatment of colon cancer but not for the
treatment of AMD, is closely related to ranibizumab. In
contrast to pegaptanib that binds only the VEGF isoforms
that are 165 kD (VEGF165) and larger [26], both
ranibizumab and bevacizumab bind and inhibit all biolog-
ically active forms of VEGF [47]. Bevacizumab is a full-
length, humanized monoclonal antibody against VEGF,
whereas ranibizumab is a humanized antigen binding
fragment against VEGF, and both proteins were genetically
engineered from the same murine monoclonal antibody
against VEGF. A major advantage of bevacizumab is its
price, which is about 1–5% the price of ranibizumab.
Mainly for this reason, it is now used worldwide and on a
large scale off-label for the treatment of exudative AMD. Its
off-label use is obviously controversial, also because the
use of anti-VEGF therapy is associated with an increased
risk for thromboembolic events. Until now, no systematic
review has shown evidence for the therapeutic effect of
bevacizumab, or its safety. In this systematic review, the
effects of bevacizumab on visual acuity (VA) and central
retinal thickness (CRT) are quantified, and the adverse




The databases searched were MEDLINE, EMBASE, and the
Cochrane database. The reference lists of included articles
and personal files were also searched until no new articles
were found. Search terms for the application in age-related
macular degeneration were “Macula*” or “AMD” or
“ARMD” or “intra(-)vitreous” or “intra-vitreal” in any field,
and for the intervention the search terms were “Bevacizu-
mab” or “Avastin” in any field. All years were included up to
March 2008. Published articles on paper, or papers available
electronically before publication on paper were included.
Language restrictions were English, German, French or
Dutch. Two observers, independently of each other, searched
the acquired list to identify relevant articles.
Selection
Articles included were randomised controlled trials, non-
randomised controlled studies, or before-and-after studies in
more than one patient. Studies with systemic or intravitreal
therapy were included. Studies were excluded that did not
have VA as the primary outcome, had as the primary
objective to study differences between subgroups, or
included also patients other than patients with exudative
AMD. All articles selected by at least one observer were
copied or printed. The ultimate selection was based on a
discussion between observers.
Data abstraction and validity assessment
Two observers read all the articles and retrieved the data.
These observers were not masked for the journal or any other
aspect of the article. Data on inclusion criteria, exclusion
criteria and adverse events were copied from a HTLM
version of the article and edited for the table. One other
observer was given only the text of the method section to
score quality items. This observer was also given a separate
results section to score the baseline and change in ETDRS
score and CRT. This observer was blinded for the results of
the other observers. Differences between observers were
discussed until a consensus was reached. The items scored
for quality of the follow-up studies were: prospective follow-
up, consecutive case series, loss to follow-up, masked
assessment of the outcome, standardized assessment of the
outcome and other interventions during the study period.
[39] The baseline value of the VA and CRT and these
scores at last examination or at the examination with
complete follow-up, when possible, were noted.
Study characteristics and outcome
Data included were author and year, type of study and
quality issues, inclusion criteria, exclusion criteria, details
of the treatment (systemic or intravitreal therapy, dosage,
frequency of dosing and criteria for additional injections),
number of patients at baseline and at follow-up and follow-
up time, baseline ETDRS and CRT and changes in these
outcomes and adverse events. The quality of the before-
and-after studies was scored according to the following
criteria often used to score quality of follow-up studies:
prospective study, consecutive cases, loss to follow-up,
blind assessment of outcome, standardized assessment of
outcome. The criterion “no other intervention” was omitted,
since studies that included such intervention were omitted
from inclusion.
The quality of the RCTs was scored with the Delphi list,
supplemented with criteria from the Dutch Cochrane Centre.
The complete list of criteria is shown in Table 2 [44].
Quantitative data analysis
The VA score was converted to the ETDRS score when the
ETDRS score was not assessed directly. We used a
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conversion of 0.1 logmar (one Snellen line) to 5 ETDRS
letters (one ETDRS line). The change in ETDRS score was
calculated as the difference between baseline value and the
value at the last examination, or at the examination when
there was no loss to follow-up. A summary for change in
ETDRS and CRT was calculated as the weighted mean of
the changes. The number of patients at the follow-up
examination determined the weight. Calculations were
made separately for intravenous injections and intravitreal
injections. The RCT arms that included the treatment with
only bevacizumab were included in the before-and-after
studies. A subgroup analysis was conducted separately for
several characteristics for the follow-up studies, which
included the following: total quality score, dosage of
intravitreal bevacizumab, previous treatment in more than
50% of patients, size of the study, duration of follow-up,
and method of assessment for visual acuity (ETDRS or
Snellen). The study quality items and results of the RCTs
were also presented. The results of the RCTs were
presented as described after conversion to ETDRS scores.
Results
The total number of articles retrieved was 561. A large
number of articles (n=535) were not included in the review
because of several reasons (Table 1). Ultimately, 26 out of
these 561 were suitable and used in the analysis. Three
randomised controlled trials were published and presented
separately [9, 27, 31]. We also combined in this review the
data of the patients of these three RCTs who had received
only intravitreal bevacizumab, and the data of patients of 23
before-and-after studies with follow-up of patients who had
received bevacizumab for exudative AMD (Tables 2, 3, 4
and 5)[1–4, 7–10, 15–18, 23, 25, 27, 29, 30–35, 37, 40, 41,
48]. A total of 1,435 patients included at baseline in these
studies were included in this review.
The three RCTs all showed that bevacizumab is more
effective than PDT (with or without triamcinolone) [9, 27,
31]. The RCTs were of a poor-to-reasonable quality and
lack of masking was the main methodological problem.
Two articles showed the results of the same study [34,
35]. Of these two, the article with the largest series of
patients and longest follow-up period was included in this
review [35]. In this study the effect of intravenous
bevacizumab in AMD was studied. Two other studies
included patients who had received intravenous bevacizu-
mab [10, 23]. The data of these three studies were included
in the summary of the effect of intravenous injections. After
intravenous bevacizumab the weighted mean change in
ETDRS score was +12.8 (range +11 to +14) and the
weighted mean change in CRT was −129 μm (range −100
to −202).
Twenty-three articles, including the patients in the RCTs
who received bevacizumab, reported the change in VA after
intravitreal bevacizumab (see Table 2) [1–4, 9, 15–18, 23, 25,
27–33, 37, 40, 48]. The weighted mean change after
intravitreal injections was 8.6 (range 2 to 26), and for the
CRT −90 (range −46 to −190). The data are summarised in
Tables 5 and 6. Inclusion criteria varied, and were composed
of: age range, VA range, recent disease progression, poor
Table 1 Flow chart for the selection of articles
Number of articles after the search 561
Reasons for not including an article
Review, comments, guidelines other reasons 228
Other eye diseases than age-related macular degeneration 133
Adverse events or safety of bevacizumab as
primary goal of study outcome
59
Other diseases than eye diseases 34
Other primary study therapy in AMD 28
Basic science or experimental studies 24
Case series 9
Kinetics and dosage study of anti-vegf 7
Study on costs 5
Study conducted to study the differences
between subgroups in effect of bevacizumab
3
Follow-up with only OCT 2
Retrospective comparison of bevacizumab
with ranibizumab (abstract only)
1
Co-interventions given 1
Not only patients with AMD included 1
Included in the study 26
Table 2 Study quality scores (according to Delphi list supplemented
with criteria from the Dutch Cochrane centre) of three randomized
controlled clinical trials that included one treatment group with
intravitreal bevacizumab
Study characteristics and outcome [9] [27] [30]
Randomization Yes Yes Yes
Allocation concealed Uk Uk Uk
Groups similar at baseline regarding
prognostic factors or were
adjustments for differences made
in the analysis
Uk Yes Yes
Eligibility criteria specified Yes Yes Yes
Other interventions applied No No No
Outcome assessor blinded No Uk Yes
Care provider blinded No No No
Patient blinded No No No
Sufficient number with follow-up Yes Yes Yes
Point estimates and measures of
variability presented
No Yes Yes
Intention to treat analysis Yes Yes Yes
Total quality score 5/11 7/11 8/11
Uk: unknown
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Table 3 Results of three randomized controlled trials that included one group that received intravitreal bevacizumab
Study Intervention Number of patients ETDRS baseline ETDRS change CRT base-line CRT change
[9] Bevacizumab 32 47 12 354 −113
PDT 30 49 −6 352 −60
[27] Bevacizumab 10 54 12 371 −138
PDT + triamcinolone 10 42 −7 346 −132
PDT + triamcinolone, reduced 10 43 0 286 −78
[30] Bevacizumab 54 31 8.6 (7.1–10.1) 355 −55 (−64 to −45)
PDT 50 31 2.5 (0.9–4.1) 356 −54 (−64 to −44)
PDT + Bevacizumab 52 33 12.3 (10.1–13.9) 349 −65 (−74 to −55)
Table 4 Study characteristics of 23 studies on the effect of bevacizumab in age-related exudative AMD










[34, 35] CNV location: subfoveal Yes No No No Yes
Lesion composition: all lesion types
if recent progression.





[23] CNV location: nn Yes No No No Yes
Lesion composition: all lesion types.
[1] CNV location: nn Yes No No No No No
Lesion composition: all lesion types.
[7] CNV location: subfoveal Yes No No No No No
Lesion composition: all lesion types, except
minimally classic CNV >4 disk
areas or those with CNV that is more
than 50% obscured by blood
[23] CNV location: subfoveal Yes No No No Yes No
Lesion composition: all active lesion types.
[3] CNV location: nn Nr Yes No No Yes No
Lesion composition: pure or predominantly
occult + recent progression.
[4] CNV location: subfoveal CNV No Yes Possible No No No
Lesion composition: all lesion types.
[30] CNV location: subfoveal lesion Yes No Possible No Yes No
Lesion composition: Minimally classic, occult
with active leakage by FAG and OCT.
[37] CNV location: nn No No No No No No
Lesion composition: all lesion types
[40] CNV location: subfoveal No Yes Yes No No No
Lesion composition: Initially patients who
responded poorly on other treatments, later
large minimally classic or occult CNV.
[48] CNV location: subfoveal No No No No Yes No
Lesion composition: all types.
[29] CNV location: subfoveal CNV No No No No Yes No
Lesion composition: all lesion types
[15] CNV location: nn Yes Yes No No No No
Lesion composition: all lesion types
[2] CNV location: subfoveal No No Possible No No No
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response to previous treatment including PDT or pegaptanib,
not eligible for PDT, previous treatment, and type of CNV. A
summary of the various exclusion criteria in these studies is
displayed in Table 5. Mostly, intravitreal injections of
1.25 mg bevacizumab were given. The strategy for addi-
tional injections differed and two main strategies could be
discerned: 1) monthly injections irrespective of the results, or
2) additional injections when vision loss reoccurred or when
macular fluid reoccurred on OCT. The mean number of
patients included at baseline who received intravitreal
injections per study was 61 (range 10–266). The weighted
mean follow-up time was 15 weeks (range 4–48). The ocular
or systemic adverse events that were reported in a total of
1,435 patients who had received an intravitreal injection, and
a total of several thousand intravitreal injections, are
summarized in Table 6. Table 7 summarizes the incidence
of reported presumed adverse events.
Table 4 (continued)










Lesion composition: all lesion types
[41] CNV location: some part of the lesion
had to involve the fovea.
No Yes Yes No No Yes
Lesion composition: submacular hemorrhage
of >50% of the lesion size.
[27] CNV location: subfoveal Yes Yes Yes No Yes No
Lesion composition: 5 occult type, 2 classic,
3 minimal classic
[18] CNV location: subfoveal No No No No Yes Yes
Lesion composition: all lesion types
[16] CNV location: subfoveal No Yes Yes No Yes Yes
Lesion composition: Refractory pigment
epithelial detachment (PED) and occult CNV
[9] CNV location: subfoveal Yes No Yes No Yes No
Lesion composition: Predominantly
classic CNV.
[8] CNV location: Subfoveal Yes No No No Yes No
Lesion composition: all types except retinal
angiomatous proliferation (RAP)
[31] CNV location: subfoveal Yes No No No Yes No
Lesion composition: minimally classic
or occult.
[33] CNV location: Mainly subfoveal No Yes No No Yes No
Lesion composition: All lesion types.
[17] CNV location: subfoveal CNV No Yes No No No No
Lesion composition: all types
[25] CNV location: nn Yes No Yes No No Yes
Lesion composition: nn
[32] CNV location: subfoveal Yes No No No No No
Lesion composition: all active lesion types
nn: not noted, CNV: choroidal neovascularisation; FAG: fluorescein angiography; OCT: optical coherence tomography.
Table 5 Summary of exclusion criteria of the 23 studies on the effect
of bevacizumab in age-related exudative AMD
Exclusion criteria mentioned
in the various articles
Reference numbers
Uncontrolled hypertension [1–4, 23, 25, 34, 35, 37, 41, 48]
Thromboembolic events:
MI, CVA
[1–4, 8, 10, 23, 25, 29, 34,
35, 37, 41, 48]
Renal abnormalities [3, 10, 23, 34, 35]
History of bleeding and / or
coagulation abnormalities
[1, 8, 23, 25, 34, 35]
Recent or planned surgery [1, 3, 8, 23, 25, 34, 35]
Any ocular condition that
may affect vision
[1, 7, 23]
Recent ocular surgery or laser [1, 23, 28]
Prior treatment for CNV [8, 9, 27]
No exclusion criteria
mentioned
[15–17, 30, 32, 33, 40]
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Table 6 Reported results of 23 studies on the effect of bevacizumab in exudative AMD














Intravenous. Two to three at 2
weeks interval. Additional
therapy according to criteria
n=18; 24 weeks 54; +14 392; −112 No serious ocular or systemic
adverse events. Increase in
systolic and diastolic blood
pressure.
[10] Intravenous. Three with 2
weeks in between
n=9; 12 weeks 54; +12.7 Not reported; −202 No serious ocular or systemic
events.
[23] Intravenous. Three with 2
weeks in between
n=12; 12 weeks 58.5; +11 337; −100 No severe adverse events
[1] Single intravitreal injection
of 2.5 mg. No additional
injections.
n=39; 4 weeks 29 (median); +15 388 (median); −141 A mild inflammatory response
in the anterior chamber was
the most common side effect




[7] Three monthly intravitreal
injections of 2.5 mg. No
additional injections
n=17; 12 Weeks 31; +26 362; −151 No serious ocular or systemic
events
[23] Three monthly intravitreal
injections of 1 mg. No
additional injections.
n=12; 12 weeks 46.6; +8.3 402; −154 No severe adverse events
[3] Single intravitreal injection of
1.25 mg. Additional injections
according to criteria
n=30; 14 weeks 46; +10 420 (median); −190 No serious ocular or systemic
events.
[4] Single intravitreal injection of
1.25 mg. Additional injections
according to criteria
n=50; 8 weeks 36; +10 not reported; −92 No serious ocular or systemic
events.
[30] Single intravitreal injection of




32, +8 378, change at
18 weeks −56
RIP in two patients. Ten PVD.
No serious ocular or systemic
events.
[37] Single intravitreal injection of
1.25 mg. Additional injections
according to criteria
n=50; 12 weeks 38.1; +7.9 351; −99.6 No serious ocular or systemic
events.
[40] Single intravitreal injection of
1.25 mg. Additional injections
according to criteria
n=141; 12 weeks 38; +11 340; −127 At 1 month, two patients had
mild vitritis, and one patient
at 2 months, who had a
history of recurrent uveitis.
No endophthalmitis,
increased intraocular pressure,
retinal tear, or retinal
detachment occurred. One
patient had MI after third
injection, one treated for TIA
stopped anti-coagulants by
himself and developed TIA.
Another possible TIA, One
death of MI (smoker with
emfysema).
[48] Single intravitreal injection of
1.25 mg. Additional injections
according to criteria
n=48; 24 weeks 36.9; +5.3 339; −73 No serious ocular or systemic
events
[29] Single intravitreal injection of
1.25 mg or 1.5 mg. Additional
n=80; 12 week 48.5; +8.6 337; −93 No serious ocular or systemic
events.
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Table 6 (continued)









(μm); mean change in
retinal thickness (μm)
Adverse events
injections according to criteria
[15] Single intravitreal injection of
1.25 mg. Additional injections
according to criteria
n=102; 10 weeks 56; +10 251; −46 No adverse ocular or systemic
events.
[2] Single intravitreal injection of




Not reported; +5.5 404; −124 No serious ocular or systemic
events.
[41] one injection of 1 mg/0.04 ml.
Additional injections according to
criteria
n=21, 16 weeks 55;+4 299;−62 No serious ocular or systemic
adverse events
[27] Three monthly intravitreal
injections of 1 mg. No
additional injections.
n=10, 12 weeks 54;+12 371;−138 No serious ocular or systemic
adverse events
[18] Single intravitreal injection of
1.25 mg. Additional injections
according to criteria
n=68, 12 weeks 51;+4 304;−68 No serious injection-related
adverse events.
[16] Single intravitreal injection of
1.25 mg. Additional injections
according to criteria
n=10, 16 weeks 21;+15 Not quantified No systemic or ocular adverse
events
[9] Three monthly intravitreal
injections of 2.5 mg
bevacizumab. Additional
injections according to criteria
n=32, 24 weeks 47;+12 354;−113 No systemic or ocular adverse
events
[8] Three monthly intravitreal
injections of 2.5 mg
bevacizumab. Additional
injections according to criteria.
n=51, 48 weeks 45.7;+7.4 327;−100 No serious ocular or systemic
events.
[31] Single injection with 1.25 mg
bevacizumab. No repeated
injections.
n=54, 12 weeks 31;+8.6 355;−55 Three pigment epithelial
ruptures, 12 PVD, four
cataract progression. Some
patients reported blurred
vision during a few days.
[33] Single intravitreal injection of
1.25 mg. Additional injections
according to criteria.
n=43, 24 weeks 48.5;+5.6 346;−87 One case of endophthalmitis.
One patient developed a
retinal pigment epithelial rip
2 weeks after treatment. No
patient had thromboembolism
or any other systemic adverse
events.
[17] Single intravitreal injection of
1.25 mg. Additional injections
according to criteria.
n=103, 8 weeks 44;+6 CRT not in every
patient conducted
One case of endophthalmitis,
three submacular
hemorrhages, and three RPE
tears.
[25] Three monthly intravitreal
injections of 1.25 mg
bevacizumab.
n=27, 12 weeks 50;+2 373;−94 Two transient corneal
epitheliopathy. Two patients
discontinued treatment due to
RPE tears. No other systemic
or ocular adverse events.
[32] Single intravitreal injection of
1.25 mg. Additional injections
according to criteria.
N=48; 15.4 weeks 32;+8 389;−51 No adverse ocular or systemic
events.
MI: myocardal infarction. RPE: retina pigment epithelium
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Studies differed in quality (Tables 4 and 8). The
difference in change in VA between subgroups according
to differences in quality was no more than 1.9 letters
(Table 8). The change in ETDRS score was 2.7 letters
higher for the studies with a higher quality. No study had a
blinded assessment of the outcome, except for one study
(but blinded only for the assessment of the CRT [10]. The
highest difference between two groups was for those who
had a higher dosage compared to those with a lower dosage
(Table 8).
Discussion
This systematic review shows that after administration of
bevacizumab in patients with exudative age-related macular
Table 7 Reported adverse
events in the 23 follow-up
studies with intravitreal injec-
tions of bevacizumab for exu-
dative AMD, in a total of 1,396
patients who received one or
more injections
Event Number of reported case Cumulative
incidence per
100 patients
Posterior vitreous detachment 24 1.7
Pigment epithelial rupture 15 1.1
Vitritis/uveitis 8 0.56
Subconjunctival hemaorrhage 3 0.21
Submacular hemaorrhage 3 0.21
Cataract progression 4 0.18
Endophthalmitis 2 0.14
Corneal epitheliopahty 2 0.14
Myocardial Infarction (MI)I 2 (one 88 years old, 2 months after third injection); 0.14
TIA 1 (stopped anti-coagulants himself) 0.07
MI death 1 (smoker with emphysema) 0.07
CVA 1 (83 years old, 34 days after second injection) 0.07
Blurred vision during few days Some patients






















Prospective study Yes 494 9.7 1.9 494 78 −24
No 661 7.8 548 102
Consecutive inclusion
of patients
Yes 510 9.0 0.7 397 99 14
No 645 8.3 645 85
Loss to follow-up Yes 478 7.9 −0.4 677 86 −10
No 677 9.7 478 96
Standardized assessment
of visual acuity
Yes 540 7.8 −1.5 530 86 −9
No 615 9.3 512 95
Quality score† ≥4 out of 5 196 10.9 2.7 186 92 2
<4 out of 5 959 8.2 856 90
Dosage ≥2 mg 139 13.3 5.3 139 120 34
<2 mg 1016 8.0 903 86
Study size >50 patients 801 8.4 −0.8 344 83 −22
≤50 patients 354 9.2 698 105
Follow-up duration ≥12 weeks 790 8.0 −1.9 780 95 17
<12 weeks 365 9.9 262 78
Previous treatment <50% of patients 621 9.0 0.8 518 93 5
≥50% of patients 534 8.2 524 88
Method of VA assessment ETDRS 530 7.2 −2.6 530 81.6 −1.2
Snellen 625 9.8 615 82.8
† as defined by the presence of >4 out of 5 of the following: prospective follow-up, consecutive case series, loss to follow-up, masked assessment
of the outcome, standardized assessment of the outcome
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degeneration, an improvement in both the VA and CRT are
reported. Moreover, bevacizumab is more efficacious than
PDT. The weighted mean increase in VA after intravitreal
bevacizumab injections in 1,396 patients is 8.6 letters on
the ETDRS score. The weighted mean decrease in CRT is
90 μm. The incidence of adverse events was low. All
studies showed an impressive effect, and the three RCTs
showed superiority of bevacizumab to PDT with or without
intravitreal triamcinolon.
The observed change in the follow-up studies of
bevacizumab is similar to the change observed after
monthly intravitreal injections of ranibizumab in exudative
age-related macular degeneration. The mean change in
ETDRS letters after monthly injections of 0.5 mg ranibizu-
mab varied between +5.9 for occult or minimally classic
CNV and +9.8 for classic CNV after 3 months [13, 38]. The
observed increase in VA is also closely similar to the
increase of 10.8 ETDRS letters after ranibizumab three
times and additional injections when necessary based on
OCT and VA change [21]. It is interesting to see that in the
1-year follow-up study of Bashur et al., fewer injections
were needed than in the 1-year follow-up study on
ranibizumab of Fung et al., with almost the same criteria
for reinjection, knowing that the intravenous half-life of
bevacizumab is 150% that of ranibizumab in rabbit eyes [5,
6, 8, 21]. However, the dosage in Bashur’s study was
2.5 mg bevacizumab.
The similarity in effect between bevacizumab and
ranibizumab is also supported by a non-randomised, single
centre comparative study in which these two drugs were
compared [42]. Baseline patient characteristics were similar
in both groups of 44 eyes in the bevacizumab group and the
53 eyes in the ranibizumab group. After 113 days of follow-
up and a mean of 1.8 injections in the bevacizumab group
the mean increase in VA was 0.8 lines. After 44 days of
follow-up and a mean of 2.0 injections of ranibizumab, the
mean increase in VA was 0.7 lines (p=0.87). The
improvement in VA is also observed in a study that
compared starting with bevacizumab to starting with
pegaptanib followed by bevacizumab [19]. In the latter
group, no statistically significant difference from baseline
was observed.
Adverse events were rare in the 1,396 patients who
received a total of several thousand intravitreal injections.
Moreover, some adverse events are the result of the procedure
(endophthalmitis, retinal detachment, cataract progression),
others are mild (vitritis), or an event may also occur as a result
of the natural course of AMD itself or with other therapies
such as photodynamic therapy and ranibizumab [14, 24].
Although the reported thromboembolic events could have
been caused by bevacizumab, the time frame between
injection and the event, the presence of additional risk
factors, the age of the population, or the increased risk of
cardiovascular diseases in patients with AMD make this less
likely. On the other hand, patients at risk of a thrombo-
embolic event were excluded in some studies.
These results confirm the results of an internet surveillance
program in which the follow-up for adverse events in 5,228
patients and 7,113 intravitreal injections with bevacizumab
from 70 centres in 12 countries was reported [20]. Adverse
events reported were corneal abrasion, lens injury, endoph-
thalmitis, retinal detachment, inflammation or uveitis, cata-
ract progression, acute vision loss, central retinal artery
occlusion, subretinal haemorrhage, retinal pigment epitheli-
um tears, blood-pressure elevation, transient ischaemic
attack, cerebrovascular accident and death. None of the
adverse event rates exceeded 0.21% [22]. These results are
also confirmed by a 12-month follow-up study of 1,265
consecutive patients with various diagnoses, including
exudative AMD, who received 4,303 intravitreal injections
of bevacizumab [46]. Systemic adverse events occurred in
eighteen patients (1.5%). These were: acute elevation of
blood pressure (0.59%), cerebrovascular accidents (0.5%),
myocardial infarction (0.4%), iliac artery aneurysms
(0.17%), toe amputation (0.17%) and deaths (0.4%). Ocular
adverse events were bacterial endophthalmitis (0.16%),
tractional retinal detachment (0.16%), uveitis (0.09%),
rhegmatogenous retinal detachment (0.02%) and vitreous
haemorrhage. Some of the adverse events may have been the
result of the underlying disease. The type and incidence of
the reported adverse events in the bevacizumab studies does
not seem to be very different from the reported type and
incidence from two large RCTs of ranibizumab [12, 38]. The
frequency of injections in the two ranibizumab RCTs was
monthly for a period of 1 year, while in the studies included
in this review only a single intravitreal injection, or three
monthly injections with or without repeated injections were
given. This treatment will ultimately lead to fewer injection-
related adverse events in the latter case.
It is known that Snellen and ETDRS visual acuities
don’t match exactly. One shortcoming of this review,
therefore, was that Snellen acuities as reported in the
various studies were converted to ETDRS scores using a
conversion of 0.1 logmar (one Snellen line) to 5 ETDRS
letters (one ETDRS line). On the other hand, for patients
with macular degeneration in the lower vision range, it
was recently shown that visual acuity measurement with
Snellen charts may underestimate VA as compared to
measurements with ETDRS charts [19]. This implies that
the visual acuity results of this systematic review, which
included several studies using Snellen charts only, may
underestimate visual acuity improvement after bevacizu-
mab as compared to the ETDRS assessments in the
ranibizumab trials. [20]
We conclude that bevacizumab is effective in improv-
ing VA in exudative AMD, and that its effect is likely to
Graefes Arch Clin Exp Ophthalmol (2009) 247:1–11 9
be equivalent to ranibizumab. According to current
reports severe adverse events for bevacizumab are rare
in the short term.
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Creative Commons Attribution NonCommercial License which
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